INTRODUCTION {#sec1-1}
============

The genus *Endolimax* appears to consist of a large number of species based on its reported occurrence in a vast range of mammals, and it has moreover been described in birds, reptiles, and amphibians. Descriptions have been based on morphology and sometimes limited to identification of a cyst stage. Analyzed specimens have been recovered from stool samples or directly from the intestinal lumen if the animal was necropsied. Recently, an ameba closely related to *Endolimax* was also recovered from various tissues of a fish (*Solea senegalensis*).\[[@ref1]\]

An overview of fundamental information such as host specificity, pathogenicity, and epidemiology is unavailable at present. A simple search for "*Endolimax*" in PubMed and Web of Science on the 26^th^ of March 2015 identified 265 and 304 articles, respectively, with an overlap of 255. The vast majority of these articles were general surveys/prevalence studies focusing on intestinal parasites in general with no particular focus on *Endolimax*. Narrowing down the search to "*Endolimax* (title)," the number of articles decreased to 19 and 25 (overlap, 19), respectively. In reality, much more work than this has been carried out on *Endolimax*, but most of the literature is relatively old and might not be indexed in the aforementioned search engines; this could also be the reason why such articles are not cited in the more recent literature. In this study, older articles were identified mainly by backtracking using already available articles, and it turned out that *Endolimax* research has been carried out by many groups that have been debating issues that can be resolved with modern day technologies. The goal of this review is therefore to provide an overview of some of the work that has been performed on *Endolimax nana* since the genus *Endolimax* was described by Kuenen and Swellengrebel\[[@ref2]\] in 1917 and the species *E. nana* by Wenyon and O'Connor\[[@ref3]\] in 1917 and Brug\[[@ref4]\] in 1918. Central topics such as morphology, taxonomy, host specificity, epidemiology, pathogenicity, diagnosis, and treatment are reviewed and discussed. Where applicable, emphasis is given on how previous discussions in the scientific community might be elucidated and resolved using state-of-the-art technology.

MORPHOLOGY AND LIFE CYCLE {#sec1-2}
=========================

*E. nana* inhabits the colon and has also been found in the appendix.\[[@ref5][@ref6][@ref7]\] Trophozoites (8--10 μm) move by pseudopodia and may reach a size of up to 30 μm during locomotion. They feed exclusively on bacteria and divide by binary fission. The nucleus is vesicular and spherical, measuring 2.0--2.5 μm, with a polymorphic karyosome.\[[@ref6][@ref7][@ref8][@ref9]\] Before excystation, the trophozoite divides without growing, producing stages that are smaller but with nuclei of the same size. At first, the cyst contains one nucleus that divides twice by mitotic division. When mature, cysts of *Endolimax* are oval and very small (6--9 μm × 5--7 μm) compared with cysts of other intestinal amebae. The cyst wall appears thin (80 nm), colorless, and smooth on the outside. In the cytoplasm, no mitochondria, Golgi apparatus, rough endoplasmic reticulum, centrioles, or microtubules are present. Uniquely among intestinal amebae, *E. nana* has elongated tubular structures consisting of ribosome-like particles.\[[@ref7][@ref9][@ref10]\] The cyst typically contains four nuclei, but it is possible that *Endolimax* may produce supernucleate cysts where up to four of the four nuclei perform an additional division, producing cysts containing 5--8 nuclei; this might, however, be a somewhat rare phenomenon.\[[@ref7][@ref9]\] Segal\[[@ref11]\] argued that the nuclei in excess of four were in fact chromatoid bodies that might be the same as the elongated tubular structures mentioned above. The nucleus has a thin nuclear membrane with chromatin deposits and no pores.\[[@ref7][@ref9][@ref10]\] The cysts are excreted in feces and may survive for up to 2 weeks when incubated at room temperature and for up to 2 months at lower temperatures; this, however, is under optimal conditions, and survival times are lower under natural settings such as in feces or water.\[[@ref6][@ref7]\] Trophozoites may survive in stool for up to 1 day when feces is incubated at room temperature.\[[@ref6]\] After ingestion, the ameba excysts by escaping through a pore in the cyst wall, divides by successive cytoplasmic bipartition into uninucleate amebae, and turn into the trophic stage.

Infection may last for many years exemplified by the experimental infection that Dobell performed on himself, which had been lasting for 17 years at the time of his last publication on *Endolimax*.\[[@ref7]\]

TAXONOMY {#sec1-3}
========

Silberman *et al*.\[[@ref12]\] performed the first DNA-based study on *E. nana* and were able to obtain a complete sequence of the *Endolimax* SSU rRNA gene. It is noteworthy that this sequence is still the only available sequence of *E. nana* in the NCBI database, despite the fact that it has been 16 years since the sequence was deposited. Compared with other amoebozoa, the SSU rRNA gene of *Endolimax* is relatively long (more than 2500 bases), which is in part due to AT-rich expansion regions, with no evidence of introns.\[[@ref12]\] In their phylogenetic analysis, Silberman *et al*.\[[@ref12]\] placed *Endolimax* as a sister taxon to the *Entamoeba* assemblage. Cavalier-Smith *et al*.\[[@ref13]\] later performed phylogenetic analyses with more sequences, including various *Mastigamoeba* sequences and placed *Endolimax* in the family Endolimacidae, which included *Endolimax* and *Endamoeba*. Sequencing the SSU rRNA gene of *Iodamoeba*, Stensvold *et al*.\[[@ref14]\] found that it grouped together with *Endolimax*, but failed to establish monophyly for *Iodamoeba*. To clarify the phylogenetic position of *Endolimax*, there was a clear need for further studies on intrageneric diversity.\[[@ref14][@ref15]\] Recently, and mostly due to availability of more sequences from related organisms, Zadrobílková *et al*.\[[@ref16]\] were able to obtain monophyly for both *Endolimax* and *Iodamoeba*.

SSU rRNA gene sequences were recently obtained from a new species identified in a sole that was named *Endolimax piscium*;\[[@ref1]\] while these sequences did cluster specifically with *E. nana*, they were highly divergent.\[[@ref16]\] However, there is still a need for additional sequences of both *E. nana* and *Endolimax* isolated from nonhuman hosts to investigate intrageneric diversity and further clarify the taxonomic status of the genus.

Meanwhile, it has proved challenging to obtain complete SSU rRNA genes from *Endolimax*. This is mostly due to the fact that general eukaryotic primers are prone to amplifying ribosomal genes that comprise fewer bases than that of *Endolimax*; for instance, *Blastocystis* has a SSU rRNA ribosomal gene of about 1800 bp, and since *Blastocystis* is very often present in stool samples positive for *Endolimax*, general primers tend to amplify *Blastocystis* preferentially over *Endolimax* when applied to genomic DNA extracted from stool. Moreover, sequences derived from *Endolimax*-positive polymerase chain reaction products often turn out to be more or less unreadable, probably for the same reasons as for *Iodamoeba*.\[[@ref14]\] It might therefore prove useful to develop phylogenies based on other genes; preferably genes such as actin that are also likely to be conserved in *Endolimax*.

HOST SPECIFICITY {#sec1-4}
================

The host specificity of *Endolimax* has been debated in the older literature.\[[@ref6][@ref17][@ref18]\] Wenrich\[[@ref19]\] stated that *Endolimax* species cannot be differentiated based on morphology and pointed out the need for experimental infection studies to investigate the host specificity of *Endolimax*. Among such studies, Dobell\[[@ref6]\] is the only person to date to have performed experimental infections on humans, namely on himself. He had examined his own feces for many years and found it to be negative for *Endolimax* before experimentally infecting himself with *Endolimax* from what was called a *Macacus sinicus*. The infection established, he was later able to infect a so-called *M. rhesus* with his own *Endolimax* isolate. Some believed in a limited host range and proposed new species names for the isolates of different animals \[[Table 1](#T1){ref-type="table"}\], whereas others\[[@ref18]\] believed that *E. nana* was able to infect a wide range of hosts. Dobell\[[@ref6]\] was more cautious in drawing conclusions before having more evidence. This confusion is also evident from the great number of *Endolimax* species described. Constenla *et al*.\[[@ref1]\] provided an overview of the different *Endolimax* species named to date \[[Table 1](#T1){ref-type="table"}\]. Arguments have been made against some of these species names, including the possibility that some were in fact *Iodamoeba* as in the case of *E. kueneni*.\[[@ref6]\] Moreover, morphological descriptions disqualify the species described as *E. reynoldsi*, which has cysts with only one nucleus,\[[@ref19]\] and some species described as distinct may in fact be the same species, for instance *E. nana*, *Endolimax gildemeisteri*, and *Endolimax cynomolgi*.\[[@ref6]\]

###### 

Species of *Endolimax* reported to date (modified from Constenla *et al*. 2014)
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There might be a need to revise the taxonomy of *Endolimax*. We have recently observed extensive genetic variation in the SSU rRNA gene among human-derived *Endolimax* (unpublished data). The only complete SSU rRNA sequence of *E. nana* available in Genbank is from a monkey (*Cercocebus albigena*) isolate,\[[@ref33]\] which clusters with only some of our unpublished human-derived sequences, indicating that there may be different ribosomal lineages infecting humans and nonhuman primates, as was already observed in the closely related genus of *Iodamoeba*.\[[@ref14]\] The genetic diversity might also explain the differences in host specificity observed between research groups, as discussed above. Yarinsky and Burrows\[[@ref34]\] observed general differences in the size of trophozoites between infected individuals suggesting the existence of at least two lineages of *Endolimax* based on this morphological characteristic. To investigate the host specificity and classification of *Endolimax* spp., DNA sequence data should be obtained from animal isolates as well as humans and analyzed by phylogenetic methods.

EPIDEMIOLOGY {#sec1-5}
============

*Endolimax* is transmitted through fecal-oral contamination of food or water.\[[@ref35][@ref36][@ref37]\] *Endolimax* cysts have been observed in drinking water from deep wells,\[[@ref38]\] on raw consumed vegetables,\[[@ref39]\] and on banknotes, which have been suggested to be potential fomites.\[[@ref40]\]

The scientific literature abounds with studies that have surveyed the prevalence of *Endolimax* in human stools samples. This can be explained by its inclusion in studies that investigate the prevalence of intestinal parasites in general, based on for instance microscopy of fecal concentrates. Due to the overwhelming number of studies, an overview of the prevalence, study groups, and methods have been included in Supplementary Table 1. We tried to estimate the global prevalence based on data from healthy individuals and including articles that were only 20 years old or less. These studies were mainly performed on schoolchildren, minority groups, or controls. By calculating weighted averages, we estimated the global prevalence in healthy individuals to be 13.4%, yielding 950,000,000 possibly infected individuals. Based on patient samples or reports in articles older than 20 years, the global prevalence is estimated to about 3.4% \[[Table 2](#T2){ref-type="table"}\]. The relatively high estimate in healthy individuals is mainly attributable to two articles from Africa where the prevalence of *Endolimax* was above 80%.\[[@ref41][@ref42]\] The inclusion of countries in Central America in the continent of North America probably leads to overestimation of the prevalence in this continent, the opposite potentially being true by the inclusion of the Middle East in Asia. In general, apparently most carriers of *E. nana* are found in Africa and South America, which comprise several developing countries. A relatively low prevalence is generally observed in studies from Asia, but the very low prevalence estimate in symptomatic patients compared with controls is mainly due to the inclusion of a large study carried out in Israel.\[[@ref43]\] It is challenging to develop a precise estimate of the prevalence of *Endolimax* in Asia due to the limited amount of data from India and China, the two most populous countries in the world. It is expected that the prevalence be overestimated from articles available due to publication bias, since it is unlikely that *E. nana* is mentioned unless observed and recorded. Likewise, there are no studies to these authors' knowledge where the prevalence of *Endolimax* is described as the primary focus of the article. On the other, it is expected that some studies have not included findings of *Endolimax* because it was considered unimportant in relation to the study aim. In addition, investigators may lack the skills to identify this parasite, including differentiating it from other amebas, as reported by Angel Núñez *et al*.,\[[@ref44]\] leading to an underestimation of the prevalence of *E. nana*.

###### 

Summary of prevalence articles used to estimate the global prevalence
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Click here for additional data file.

###### 

Estimated prevalence of *Endolimax nana* by continent and globally
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CLINICAL SIGNIFICANCE {#sec1-6}
=====================

*Endolimax* is considered a nonpathogenic commensal protozoon parasitizing the human colon;\[[@ref6][@ref9]\] this or a similar description is given in most textbooks.\[[@ref37][@ref45][@ref46][@ref47]\] The evidence supporting *Endolimax* as nonpathogenic is scarce, but in the study where Dobell\[[@ref6]\] infected himself, the author did not experience any symptoms. Dobell\[[@ref6]\] performed postmortem examination of infected monkeys and failed to discover any amebic lesions of the intestine. Some authors have argued that *Endolimax* can cause irritation of the crypts of the intestinal mucosa, referring to observations by Swerdlow and Burrows;\[[@ref48]\] the empirical data to support such a statement are limited, however, since this report is on *Dientamoeba fragilis* and only one case was co-infected with *Endolimax*.

It is common to find reports on associations between diarrhea and *Endolimax* infections.\[[@ref49][@ref50][@ref51][@ref52]\] This association may at least in part be explained by *Endolimax* being an indicator of fecal contamination, which may often entail co-infection by other organisms capable of causing diarrhea. In a couple of case studies, *Endolimax* was associated with chronic diarrhea;\[[@ref52][@ref53][@ref54]\] all cases responded well to treatment, and it was not possible to detect other infections except in the study by Shah *et al*.\[[@ref52]\] where one case was co-infected with *Blastocystis*. It is possible that the cysts in the study published by Fitzgerald and O'Farrell\[[@ref53]\] are not *Endolimax* cysts since they were described as having only one nucleus. Twelve cases were described in the study by Sanchez\[[@ref55]\] who concluded that *E. nana* is possibly pathogenic.

There are also case studies that associate *E. nana* with urticaria\[[@ref56]\] and polyarthritis.\[[@ref57]\] Alarcón-Segovia and Abud-Mendoza\[[@ref58]\] objected to the latter study, which was followed by a reply from Liakos and Burnstein\[[@ref59]\] in the same journal issue. The objections included that no tests of reactive arthritis were performed, that *Endolimax* is presumably noninvasive, and that the treatment with metronidazole could eradicate other disease-causing organisms; in addition, no efforts were made to investigate whether any such organisms were present. The reply stated that testing did not reveal any other pathogenic organisms, but that such organisms could possibly be present. There is some evidence that *Endolimax* may give rise to an immunological response, including eosinophilia.\[[@ref60][@ref61]\] There are no known cases of *Endolimax* crossing the intestinal barrier in humans; however, *E. piscium* was recently described in a sole in both intestinal and nonintestinal tissue.\[[@ref1]\]

The authors of this review are of the opinion that the sporadic articles on *E. nana* present too little evidence in favor of the assertion that *Endolimax* should be considered pathogenic with the ability to cause diarrhea or intestinal inflammation. The clinical picture may be subtle, however, and it has been suggested that symptoms may develop if a heavy infection is present\[[@ref54]\] or that the pathogenicity might be limited to particularly virulent strains.\[[@ref59]\]

DIAGNOSIS AND TREATMENT {#sec1-7}
=======================

The diagnosis of *Endolimax* traditionally relies on microscopy of cysts, which can be direct or coupled with a concentration procedure and different stains prior to analysis. Concentration can be formalin-based \[[Figure 1a](#F1){ref-type="fig"}\], and when the fecal concentrate is stained with iodine, cysts of *E. nana* appear gibbous\[[@ref7]\] \[[Figure 1b](#F1){ref-type="fig"}\]. This gibbous appearance is however not always present and almost absent when cysts are concentrated using a sucrose gradient and stained with iodine \[[Figure 1c](#F1){ref-type="fig"}\]. The cysts of *Endolimax* and *E. hartmanni* both have four nuclei but can be differentiated by *E. nana* having a larger punctuate karyosome and peripheral chromatin, both of which features however may be quite difficult to discern.\[[@ref8][@ref47]\] *Endolimax* stains with both Ziehl--Neelsen and trichrome. Cysts of *E. nana* are some of the smallest among those of the amebas, which is why it is recommended to use a microscope with at least ×400 magnification to avoid missing them but also in order to be able to distinguish them from *E. hartmanni*. A large number of cysts may be excreted compared with other amebae (*Entamoeba coli*, *E. histolytica*/*E. dispar*), with an estimate of about 8000 cysts/g, but with a few "heavy shedders." It is possible that *Endolimax* is shed periodically.\[[@ref62]\] Trophozoites are rarely observed, unless direct examination is performed on fresh stool samples \[[Figure 1d](#F1){ref-type="fig"}\].

![Cysts of *Endolimax nana* in direct smear (a), concentrated with formalin and ethyl acetate and stained with iodine showing the characteristic gibbous appearance (b), and isolated on a sucrose gradient and stained with iodine, respectively (c). Image (d) shows a *Endolimax nana* trophozoite](TP-6-8-g003){#F1}

Based on the single SSU rRNA gene sequence in GenBank, in-house primers have been developed \[[Table 3](#T3){ref-type="table"}\] that have proved partially effective for diagnosing *E. nana* in genomic DNA extracted from fresh stool. It was from sequences generated using these primers that the high variation in the SSU rRNA genes mentioned previously was observed. Meanwhile, DNA from microscopy-positive samples have sometimes failed to show amplification with these primers. Due to the high variation in SSU rDNA (unpublished observations), designing genus-specific primers based on a single sequence or only a few sequences is problematic. There is a need for more reference sequences to develop better diagnostic primers that also eliminates selection for specific *Endolimax* strains. It is currently unknown whether the primers included in [Table 3](#T3){ref-type="table"} will also amplify *Endolimax* from hosts other than humans.

###### 

In-house primers for detecting and characterizing *Endolimax*
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*Endolimax* appears to respond well to both metronidazole and diphetarsone treatment. Stauffer and Levine\[[@ref54]\] were able to treat two cases with metronidazole, although it appears that two courses of treatment were necessary in one of the cases. The same treatment with metronidazole was successful in a single case in the study by Burnstein and Liakos.\[[@ref57]\] Based on these two studies, Graczyk *et al*.\[[@ref51]\] recommend metronidazole for *Endolimax* treatment, administered as 250 mg 3 times a day for 10 days. In a study by Keystone *et al*.,\[[@ref63]\] a 98% cure rate (*n* = 44) was observed with diphetarsone 500 mg 3 times a day for 10 days. *In vitro* studies have revealed little effect of streptomycin\[[@ref64]\] and emetine\[[@ref6]\] on *Endolimax*. Treatment of concurrent pathogenic parasites revealed little effect on *Endolimax* using emetine\[[@ref6]\] or mebendazole.\[[@ref35]\]

CONCLUSIONS {#sec1-8}
===========

Based on available data, the global prevalence of *E. nana* in healthy individuals is estimated to be 13.9% on average, which, however, is probably an overestimation as discussed above; still, hundreds of millions are most likely infected. Very little research has been performed on *Endolimax* since the 1920s, 30s, and 40s. With the availability of DNA-based detection methods, resolving major issues such as host specificity, diversity, and which *Endolimax* species that can infect humans should be straightforward. In addition, the development of diagnostic primers will allow *Endolimax* to be detected with high sensitivity using fecal DNAs and distinguished easily from other amebae. The clinical significance of *Endolimax* is still an unresolved issue. Prior exposure (immunity), parasite load, and genetic variability might influence clinical presentation. Little evidence points toward *Endolimax* being pathogenic, but a few articles provide data on *Endolimax*-based stimulation of the immune system; whether this is a harmful or beneficial modulatory effect remains unknown. Hopefully, the present review will stimulate interest in *Endolimax* research, which may eventually render *Endolimax* a not so inconspicuous companion.
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